<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380350</url>
  </required_header>
  <id_info>
    <org_study_id>TREAT</org_study_id>
    <nct_id>NCT04380350</nct_id>
  </id_info>
  <brief_title>Trenza Embolization Device for Intrasaccular Aneurysm Treatment</brief_title>
  <official_title>Trenza Embolization Device for Intrasaccular Aneurysm Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Neurovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Neurovascular</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Post-Market Clinical Follow-up study is to assess the safety and&#xD;
      performance of the Trenza in the treatment of intracranial aneurysms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, single-arm, post-market follow-up study conducted in Europe for&#xD;
      the treatment of patients with saccular intracranial aneurysms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety primary outcome measure</measure>
    <time_frame>1 year (± 6 months)</time_frame>
    <description>Stroke-related neurologic death, or major ipsilateral or disabling stroke in the territory supplied by the treated artery, occurring within 12 months post-procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness primary outcome measure</measure>
    <time_frame>1 year (± 6 months)</time_frame>
    <description>Adequate aneurysm occlusion without retreatment or significant parent artery stenosis (&gt;50% stenosis) using Raymond Roy classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety secondary outcome measure</measure>
    <time_frame>1 year (± 6 months)</time_frame>
    <description>Any stroke event occurring through 12 months post-procedure</description>
  </secondary_outcome>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Aneurysm</condition>
  <condition>Intracranial Aneurysm</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with Trenza device&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Has a single, target intracranial aneurysm that is suitable for endovascular treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Target aneurysm has been previously treated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Christophe Cognard, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Purpan, Toulouse, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence Sockeel</last_name>
    <phone>+1 510-413-2400</phone>
    <email>florence.sockeel@stryker.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richelle Massey</last_name>
    <phone>+1 510-413-2400</phone>
    <email>richelle.massey@stryker.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe Cognard, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

